Verily, Alphabet’s life sciences spinoff, has invested in Freenome, a Bay Area biotech startup working on detecting early-stage cancer.
Verily backed Freenome in its $65 million Series A round in March, according to CNBC. The Verily investment was separate from the previously reported Series A investment by Alphabet’s venture unit, GV.
Verily does not typically back companies, preferring to partner with other life science startups. In this case, Verily not only put up funds, but also constructed…
Verily, Alphabet’s life sciences spinoff, has invested in Freenome, a Bay Area biotech startup working on detecting early-stage cancer.
Verily backed Freenome in its $65 million Series A round in March, according to CNBC. The Verily investment was separate from the previously reported Series A investment by Alphabet’s venture unit, GV.
Verily does not typically back companies, preferring to partner with other life science startups. In this case, Verily not only put up funds, but also constructed…